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Atopic dermatitis (AD) is a chronic relapsing inflammatory 
skin disease [1]. It affects 10%-20% of children, the most 
prevalent form being chronic disease, and 1%-3% of adults, 
particularly in the most developed Western societies [1-3]. 
Fifty percent of cases resolve during adolescence, with up to 
20% of cases persisting into adulthood and a prevalence of 
1%-3% in patients aged more than 60 years [4]. 
Available evidence on the prevalence of severe AD is 
uncertain and scarce at the population level. No studies on 
the prevalence of AD have focused on Spain. The main goal 
of this study was to describe the prevalence of severe AD in 
routine clinical practice at different locations in Spain. As 
a secondary goal, associated comorbidities and therapeutic 
approaches were described. 
A cross-sectional (prevalence) study was conducted based 
on a review of medical registries (digital databases, dissociated 
data). The study population was obtained from health care 
providers’ registries, which were unified in the dissociated 
database of the RedISS (Red de Investigación en Servicios 
Sanitarios) Foundation. Data came from the OMIap digital 
clinical history and other complementary databases. Registries 
from patients in Asturias, Catalonia, and the Balearic Islands 
were obtained. Patients who required healthcare services 
during 2015-2016 were included. The inclusion criteria were 
age ≥18 years, registered diagnosis of severe AD at least 12 
months before the study, inclusion in the prescription program 
(registered daily dose, timing and duration of each treatment; 
≥2 prescriptions during the follow-up period), and ability to 
guarantee regular follow-up (≥2 health registries in the system; 
at least 1 visit to the dermatology service). The exclusion 
criteria were change in health center or move outside the study 
areas, permanent hospitalization, and history of seborrheic 
dermatitis, contact dermatitis, and/or dyshidrotic eczema. 
Registries of patients with AD were obtained from the 
International Classification of Primary Care in the European 
Union [5] (codes S87, S88) and/or the International 
Classification of Disease (Ninth Edition), Clinical Modification 
(ICD-9-CM; 691.8, 692.9, 706.8), which include AD, 
allergic dermatitis, allergic eczema, atopic eczema, atopic 
neurodermatitis, and xerosis. AD was diagnosed by the physician 
(reference dermatologist) according to the criteria of Hanifin 
and Rajka [6] (AD present for over 1 year). AD was considered 
severe when the patient received an immunosuppressant 
(cyclosporine, methotrexate, azathioprine, mycophenolate 
mofetil) or a biologic (omalizumab, rituximab) during follow-
up or had been hospitalized because of AD. Furthermore, 
administration of systemic corticosteroids and other treatments 
(immunoglobulins, interferon g, hydroxychloroquine, alefacept) 
received by the patient was registered. Data were obtained from 
registries of pharmaceutical dispensation and hospital pharmacy 
services (Anatomical Therapeutic Chemical Classification 
System) [7]. Age (continuous and by range), sex, and associated 
comorbidities [5] (Table) were also obtained. Prevalence was 
calculated as the number of patients diagnosed with AD seen 
by a dermatologist and treated with immunosuppressants 
or biologics and/or hospitalized (numerator) divided by the 
number of individuals assigned to their primary care centers 
(denominator). Moreover, data were validated to ensure the 
quality of the results. A descriptive univariate statistical analysis 
was conducted for variables of interest, and the 95% confidence 
intervals (CI) were calculated. A bivariate analysis was 
conducted with ANOVA and c2 tests (SPSSWIN, Version 19). 
Statistical significance was set at P<.05).
Out of an initial selection of 935 894 individuals aged ≥18 
years assigned to the centers, 777 patients were included in 
the study. The prevalence of severe AD in adults was 0.08% 
(95%CI, 0.07-0.09%) (Table), with mild variability between 
the different geographical areas analyzed due to a statistical 
effect with no epidemiological significance. The average time 
after diagnosis was 29.2 years. The average age was 52.6 years, 
and 64.5% of patients were women. Morbidity associated 
with severe AD was high: arterial hypertension, 37.6%; 
dyslipidemia, 29.3%; asthma, 24.4%; depression, 21.4%; and 
allergic rhinitis, 19.4%. In patients with severe AD, the most 
widely used specific medications were cyclosporine (46.3%), 
methotrexate (21.2%), and mycophenolate mofetil (19.6%); 
1.2% of patients were hospitalized. Of note, 55.2% of these 
patients (n=777) were prescribed systemic corticosteroids. 
Sociodemographic characteristics, comorbidities, and 
medication were homogeneous in the individual geographical 
areas, thus adding consistency to the results. There were no 
deaths during the follow-up period.
The study results show that the prevalence of severe AD 
in adults is low in the 3 areas analyzed, thus reinforcing the 
hypothesis that the high variability in prevalence observed in 
published data could be due to the quality of registries and 
the method used to create them. Few observational studies 
focus on a real-life setting, thus hampering data comparison. 
Consequently, study results should be interpreted cautiously, 
particularly when it comes to external validity. 
Although data are lacking, the prevalence of severe AD 
is estimated to be around 5%, whereas that of general AD 
could be around 2% [8,9]. In a hypothetical and cautious 
scenario of a general adult prevalence of 2% for AD and 5% 
for severe AD, our results seem to be consistent with these 
conclusions, even if they are significantly lower. In addition, 
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the waxing and waning nature of the signs and symptoms, the 
fact that severity is rarely substantially modified for a single 
patient, and a possible bias in disease classification could, 
to our understanding, lead us to underestimate severe cases. 
Considering the comorbidities (Table), our results seem to be 
in accordance with available data [2,9,10]. 
The limitations of the present study include a possible bias 
in patient classification and the therapeutic groups selected, 
since patients required immunosuppressants. In addition, the 
number of AD cases may have been underestimated through 
under-recording of disease (classification code) or possible 
variability between patients and professionals. Therefore, it 
is difficult to generalize our findings.
More studies will be needed to determine the real 
epidemiology of the disease. Future studies will require assays 
to improve diagnosis and treatment of AD, as well as to replicate 
the study. In conclusion, based on the inclusion criteria used in 
this study, the prevalence of severe AD in adults is low.
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Table. General Characteristics, Comorbidities, and Medication Administered by Geographical Area
Study groups Asturias Catalonia Balearic Islands Total P Value 
Number of patients 105 380 292 777  
Study population 124 558 408 377 402 959 935 894 
Estimated prevalence, % 0.08% 0.09% 0.07% 0.08% .001 
95% Confidence interval  0.04%-0.12% 0.07%-0.011% 0.06%-0.08% 0.07%-0.09%  
Sociodemographic characteristics       
Mean (SD) age, y 52.6 (17.0) 53.4 (15.1) 51.7 (16.0) 52.6 (15.7) .349 
Range:   18-44 years 32.4% 28.4% 29.8% 29.5%  
               45-64 years 40.0% 43.7% 44.5% 43.5%  
               ≥65 years 27.6% 27.9% 25.7% 27.0% .888 
Sex (female) 63.8% 65.3% 62.3% 64.0% .734 
Time since diagnosis, years  30.2 (9.3) 28.5 (8.3) 29.9 (9.0) 29.2 (8.7) .044
Comorbidity      
 Arterial hypertension  36.2% 39.7% 35.3% 37.6% .472 
 Diabetes mellitus 13.3% 13.2% 10.6% 12.2% .568 
 Dyslipidemia 28.6% 28.9% 30.1% 29.3% .929 
 Obesity 11.4% 19.5% 15.1% 16.7% .093 
 Active smoking 16.2% 18.4% 13.4% 16.2% .210 
 Alcoholism 7.6% 5.8% 8.6% 7.1% .371 
 Ischemic heart disease 2.9% 3.2% 1.4% 2.4% .317 
 Asthma 21.0% 27.6% 21.6% 24.5% .130 
 Allergic rhinitis 19.0% 19.7% 19.2% 19.4% .978 
 Nasal polyposis 9.5% 9.2% 7.9% 8.8% .795 
 Dementia 3.8% 0.5% 1.0% 1.2% .057 
 Neuropathy 6.7% 5.0% 2.7% 4.4% .170 
 Depression 18.1% 23.9% 19.2% 21.4% .222 
 Anxiety 15.2% 16.3% 17.5% 16.6% .852 
 Malignant neoplasm 13.3% 13.2% 13.0% 13.1% .996
Medication administered           
 Cyclosporine 49.5% 48.9% 41.8% 46.3% .241 
 Methotrexate 22.9% 19.2% 23.3% 21.2% .400 
 Azathioprine 11.4% 8.7% 10.3% 9.7% .632 
 Mycophenolate mofetil 18.1% 19.4% 20.9% 19.6% .634 
 Omalizumab 0.0% 1.8% 3.1% 2.0% .149 
 Rituximab 0.0% 2.4% 3.4% 2.4% .148
Patients hospitalized, % 1.9% 1.6% 0.3% 1.2% .247
Associated medication      
 Systemic corticosteroids 58.1% 57.6% 51.0% 55.2% .190 
 Other drugs 2.9% 5.0% 3.1% 4.0% .369
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Allergy to donkey milk (DM) is a rare clinical condition, 
not only because DM is not widely consumed, but also because 
of its hypoallergenic nature. In fact, the major cow milk (CM) 
allergens, κ-casein and αs1-casein, are very minor components 
of the casein contained in DM, which shows higher homology 
with the human counterpart than with the bovine one [1]. 
Because of its hypoallergenic properties, DM is considered 
a useful alternative for children affected by CM protein 
allergy [2] and by CM food protein–induced enterocolitis 
syndrome, as recently demonstrated in a pilot study [3].
We report the case of a 35-year-old woman with a history 
of cat dander allergy since childhood, seasonal allergic rhinitis, 
and asthma related to grass and olive pollen who was sensitized 
to house dust mites but had no history of food allergy. The 
patient developed respiratory allergy to DM characterized 
by rhinoconjunctivitis and asthma. The initial symptoms 
(rhinitis and mild wheeze) occurred 8-10 months after short 
but repetitive exposure to DM in the food analysis laboratory 
where she worked. Considering that she handled DM in 
both liquid form (raw and pasteurized) and powdered form 
(lyophilized DM), sensitization may have been percutaneous 
or by inhalation. A few months after the onset of respiratory 
symptoms, she experienced oral pruritus, cough, dyspnea, and 
wheezing immediately after tasting ultra-high-temperature 
(UHT) processed DM. Her symptoms resolved completely 
after 20 minutes with inhaled salbutamol (400 µg) and the 
oral antihistamine rupatadine (10 mg). From that episode on, 
she avoided all contact with DM but continued to tolerate CM 
and dairy products.
In order to characterize the patient’s allergic reaction, we 
performed the following in vivo and in vitro tests: skin prick 
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